Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Koschmieder, Steffen; Isfort, Susanne; Schulte, Clemens; Jacobasch, Lutz; Geer, Thomas; Reiser, Marcel; Koenigsmann, Michael; Heinrich, Bernhard; Wehmeyer, Jürgen; von der Heyde, Eyck; Tesch, Hans; Gröschl, Benedikt; Bachhuber, Petra; Großer, Susanne; Pahl, Heike L.

Ann Hematol ; 102(12): 3383-3399, 2023 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-37792065

2.

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.

Peeken, Jan C; Jutzi, Jonas S; Wehrle, Julius; Koellerer, Christoph; Staehle, Hans F; Becker, Heiko; Schoenwandt, Elias; Seeger, Thalia S; Schanne, Daniel H; Gothwal, Monika; Ott, Christopher J; Gründer, Albert; Pahl, Heike L.

Blood ; 131(18): 2065-2073, 2018 05 03.

Artículo en Inglés | MEDLINE | ID: mdl-29519804

3.

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.

Stosch, Juliane M; Heumüller, Anezka; Niemöller, Christoph; Bleul, Sabine; Rothenberg-Thurley, Maja; Riba, Julian; Renz, Nathalie; Szarc Vel Szic, Katarzyna; Pfeifer, Dietmar; Follo, Marie; Pahl, Heike L; Zimmermann, Stefan; Duyster, Justus; Wehrle, Julius; Lübbert, Michael; Metzeler, Klaus H; Claus, Rainer; Becker, Heiko.

Br J Haematol ; 182(6): 830-842, 2018 09.

Artículo en Inglés | MEDLINE | ID: mdl-29974943

4.

Sentinel mutations: the roses in the vineyard.

Pahl, Heike L.

Blood ; 138(21): 2019-2020, 2021 11 25.

Artículo en Inglés | MEDLINE | ID: mdl-34821937

5.

Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.

Limberger, Kathrin A; Bogatyreva, Lioudmila; Todorova, Rumyana; Herde, Bettina; Hauschke, Dieter; Pahl, Heike L; Werner, Martin; Aumann, Konrad.

Histochem Cell Biol ; 147(1): 75-82, 2017 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-27544663

6.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer, Holly L; Kosiorek, Heidi; Dueck, Amylou C; Scherber, Robyn; Slot, Stefanie; Zweegman, Sonja; Te Boekhorst, Peter Aw; Senyak, Zhenya; Schouten, Harry C; Sackmann, Federico; Fuentes, Ana Kerguelen; Hernández-Maraver, Dolores; Pahl, Heike L; Griesshammer, Martin; Stegelmann, Frank; Döhner, Konstanze; Lehmann, Thomas; Bonatz, Karin; Reiter, Andreas; Boyer, Francoise; Etienne, Gabriel; Ianotto, Jean-Christophe; Ranta, Dana; Roy, Lydia; Cahn, Jean-Yves; Harrison, Claire N; Radia, Deepti; Muxi, Pablo; Maldonado, Norman; Besses, Carlos; Cervantes, Francisco; Johansson, Peter L; Barbui, Tiziano; Barosi, Giovanni; Vannucchi, Alessandro M; Paoli, Chiara; Passamonti, Francesco; Andreasson, Bjorn; Ferrari, Maria L; Rambaldi, Alessandro; Samuelsson, Jan; Cannon, Keith; Birgegard, Gunnar; Xiao, Zhijian; Xu, Zefeng; Zhang, Yue; Sun, Xiujuan; Xu, Junqing; Kiladjian, Jean-Jacques; Zhang, Peihong.

Haematologica ; 102(1): 85-93, 2017 01.

Artículo en Inglés | MEDLINE | ID: mdl-27540137

7.

Many roads lead to MPN.

Pahl, Heike L.

Blood ; 123(14): 2133-4, 2014 Apr 03.

Artículo en Inglés | MEDLINE | ID: mdl-24700715

8.

A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy.

Gothwal, Monika; Wehrle, Julius; Aumann, Konrad; Zimmermann, Vanessa; Gründer, Albert; Pahl, Heike L.

Haematologica ; 101(9): 1054-64, 2016 09.

Artículo en Inglés | MEDLINE | ID: mdl-27479815

9.

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Aumann, Konrad; Frey, Anna-Verena; May, Annette M; Hauschke, Dieter; Kreutz, Clemens; Marx, Jan P; Timmer, Jens; Werner, Martin; Pahl, Heike L.

Blood ; 122(1): 93-9, 2013 Jul 04.

Artículo en Inglés | MEDLINE | ID: mdl-23670178

10.

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.

Jutzi, Jonas S; Pahl, Heike L.

Mediators Inflamm ; 2015: 101987, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-26543325

11.

A JAK-in-the-cell cycle.

Pahl, Heike L.

Blood ; 119(5): 1096-7, 2012 Feb 02.

Artículo en Inglés | MEDLINE | ID: mdl-22308276

12.

Ponatinib: a third-generation inhibitor for the treatment of CML.

Wehrle, Julius; Pahl, Heike L; von Bubnoff, Nikolas.

Recent Results Cancer Res ; 201: 99-107, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-24756787

13.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Fleischman, Angela G; Aichberger, Karl J; Luty, Samuel B; Bumm, Thomas G; Petersen, Curtis L; Doratotaj, Shirin; Vasudevan, Kavin B; LaTocha, Dorian H; Yang, Fei; Press, Richard D; Loriaux, Marc M; Pahl, Heike L; Silver, Richard T; Agarwal, Anupriya; O'Hare, Thomas; Druker, Brian J; Bagby, Grover C; Deininger, Michael W.

Blood ; 118(24): 6392-8, 2011 Dec 08.

Artículo en Inglés | MEDLINE | ID: mdl-21860020

14.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

Wehrle, Julius; Seeger, Thalia S; Schwemmers, Sven; Pfeifer, Dietmar; Bulashevska, Alla; Pahl, Heike L.

Haematologica ; 98(7): 1073-80, 2013 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-23445878

15.

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

Zhang, Yu Wei; Velasco-Hernandez, Talia; Mess, Julian; Lalioti, Maria-Eleni; Romero-Mulero, Mari Carmen; Obier, Nadine; Karantzelis, Nikolaos; Rettkowski, Jasmin; Schönberger, Katharina; Karabacz, Noémie; Jäcklein, Karin; Morishima, Tatsuya; Trincado, Juan Luis; Romecin, Paola; Martinez, Alba; Takizawa, Hitoshi; Shoumariyeh, Khalid; Renders, Simon; Zeiser, Robert; Pahl, Heike L; Béliveau, François; Hébert, Josée; Lehnertz, Bernhard; Sauvageau, Guy; Menendez, Pablo; Cabezas-Wallscheid, Nina.

Blood Adv ; 7(24): 7525-7538, 2023 12 26.

Artículo en Inglés | MEDLINE | ID: mdl-37639313

16.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Wang, Wei; Schwemmers, Sven; Hexner, Elizabeth O; Pahl, Heike L.

Blood ; 116(2): 254-66, 2010 Jul 15.

Artículo en Inglés | MEDLINE | ID: mdl-20339092

17.

Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.

Duque-Afonso, Jesús; Solari, Leticia; Essig, Aitomi; Berg, Tobias; Pahl, Heike L; Lübbert, Michael.

Br J Haematol ; 153(5): 612-22, 2011 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-21488857

18.

Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice.

Huai, Jisen; Firat, Elke; Nil, Ahmed; Million, Daniele; Gaedicke, Simone; Kanzler, Benoit; Freudenberg, Marina; van Endert, Peter; Kohler, Gabriele; Pahl, Heike L; Aichele, Peter; Eichmann, Klaus; Niedermann, Gabriele.

Proc Natl Acad Sci U S A ; 105(13): 5177-82, 2008 Apr 01.

Artículo en Inglés | MEDLINE | ID: mdl-18362329

19.

Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.

Basu, Titiksha; Bertrand, Hannah; Karantzelis, Nikolaos; Gründer, Albert; Pahl, Heike L.

Hemasphere ; 5(5): e565, 2021 May.

Artículo en Inglés | MEDLINE | ID: mdl-33954282

20.

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry.

Gecht, Judith; Tsoukakis, Ioannis; Kricheldorf, Kim; Stegelmann, Frank; Klausmann, Martine; Griesshammer, Martin; Schulz, Holger; Hollburg, Wiebke; Göthert, Joachim R; Sockel, Katja; Heidel, Florian H; Gattermann, Norbert; Maintz, Christoph; Al-Ali, Haifa K; Platzbecker, Uwe; Hansen, Richard; Hänel, Mathias; Parmentier, Stefani; Bommer, Martin; Pahl, Heike L; Lang, Fabian; Kirschner, Martin; Isfort, Susanne; Brümmendorf, Tim H; Döhner, Konstanze; Koschmieder, Steffen.

Cancers (Basel) ; 13(16)2021 Aug 13.

Artículo en Inglés | MEDLINE | ID: mdl-34439237

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.

Sentinel mutations: the roses in the vineyard.

Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Many roads lead to MPN.

A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy.

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.

A JAK-in-the-cell cycle.

Ponatinib: a third-generation inhibitor for the treatment of CML.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.

Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice.

Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry.